Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 881 - 888 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC4504 | Nefiracetam |
|
Cognitive enhancer that displays various pharmacological effects. Activates L/N-type calcium channels, cholinergic, monoaminergic and GABAergic systems. Displays potent neuroprotective action in the retinal ischemia-reperfusion model in vivo.
|
|
| BCC4510 | GSK-3 Inhibitor IX (BIO) |
|
Potent and selective, ATP-competitive glycogen synthase kinase-3 (GSK-3) inhibitor (IC<sub>50</sub> values are 5, 83, 300, 320 and > 10 000 nM at GSK-3, CDK5/p25, CDK2/cyclin A, CDK1/cyclin B and other common kinases respectively). Maintains self-renewal and pluripotency in embryonic stem cells via activation of the Wnt signaling pathway <em>in vitro</em>; also promotes proliferation and dedifferentiation in cardiomyocytes. Negative control available.
|
|
| BCC4513 | Mubritinib (TAK 165) |
|
Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.
|
|
| BCC4514 | Tyrphostin AG 879 |
|
Inhibitor of the tyrosine kinase activity of nerve growth factor (NGF) TrkA. Decreases cellular proliferation in human muscular sarcoma cell lines. Also inhibits ErbB2 and VEGFR-2 (IC<sub>50</sub> values are approximately 1 <span class='symbol'>μ</span>M for both).
|
|
| BCC4517 | Cetirizine DiHCl |
|
Histamine H<sub>1</sub> receptor antagonist that displays selectivity over other receptors at concentrations up to 10 <span class='symbol'>μ</span>M. A non-sedating antihistamine that inhibits histamine release and eosinophil chemotaxis during secondary phase allergic response. Inhibits activation of eosinophils, neutrophils and monocytes <em>in vivo</em>.
|
|
| BCC4527 | Cimetidine |
|
Widely used H<sub>2</sub> histamine antagonist which has more recently been described as an inverse agonist. Also a potent I<sub>1</sub> imidazoline binding site ligand.
|
|
| BCC4528 | Clemastine Fumarate |
|
H1-receptor antagonist. Enhances differentiation of oligodendrocyte progenitor cells into myelin basic protein-positive oligodendrocytes in vitro and promotes remyelination in vivo. Also displays antimuscarinic properties. Clinically-used antihistamine.
|
|
| BCC4530 | Histamine 2HCl |
|
Endogenous agonist at histamine receptors (H1-4). Released from mast cells and basophils and exhibits inflammatory, vasodilatory and bronchoconstrictory activity. Stimulates gastric acid secretion and acts as a neurotransmitter in vivo.
|
|